NCT03049579 is a NA clinical trial of Weiquan Yogurt with probiotics in Flu Symptom, sponsored by Hangzhou Wei Chuan Foods Co., Ltd..

Who is sponsoring NCT03049579?

NCT03049579 is sponsored by Hangzhou Wei Chuan Foods Co., Ltd..

What drugs are being tested in NCT03049579?

Interventions in NCT03049579: Weiquan Yogurt with probiotics, Weiquan Yogurt without probiotics.

What condition does NCT03049579 study?

NCT03049579 studies Flu Symptom.

Is NCT03049579 still recruiting?

NCT03049579 is currently completed. Last updated 10 February 2017.

Last reviewed 2017-02-10 · How we verify

NCT03049579

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immune System Stimulation by Probiotic Food Supplementation

Completed NA Last updated 10 February 2017

What this trial tests

NA trial testing Weiquan Yogurt with probiotics in Flu Symptom in 136 participants. Completed in 2 May 2016.

Timeline

8 January 2016

Primary endpoint
10 April 2016

2 May 2016

Quick facts

Lead sponsor	Hangzhou Wei Chuan Foods Co., Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	136
Start date	8 January 2016
Primary completion	10 April 2016
Estimated completion	2 May 2016

Drugs / interventions tested

Weiquan Yogurt with probiotics
Weiquan Yogurt without probiotics

Conditions studied

Flu Symptom — all drugs for Flu Symptom →

Sponsor

Hangzhou Wei Chuan Foods Co., Ltd.

Who can join

Adults 25 to 45, any sex, with Flu Symptom. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effects of a probiotic supplementation on adult volunteers with having caught the common cold more than 4 times in the past year. This study is a single center, double-blind, randomized, controlled, parallel-designed, prospective trial. Subjects received a probiotic drink containing probiotics of Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacilluscasei431® (108CFU/ml) and Lactobacillus fermentiumPCC® (106CFU/ml) or an identical placebo without probiotics for a 12-week study period. The incidence of flue and cold during the study period were compared between study groups. Blood and fecal samples were collected at baseline and at the end of the intervention. Fecal samples were collected for the secretory immunoglobulin A (sIgA) analysis. Blood sample was drawn for interferon γ (IFN-γ), interleukin 4 (IL-4), interleukin 10 (IL-10), immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03049579 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hangzhou Wei Chuan Foods Co., Ltd.
Last refreshed: 10 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03049579.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing